THE DEAL, AT A GLANCE
2/4 reviewedRougeTx
RougeTx
RougeTx develops oral medicines to stabilize fragile blood vessels in inherited bleeding disorders.
RougeTx raised $58M Series A, announced 2026-10-0701What it doesRougeTx develops oral medicines to stabilize fragile blood vessels in inherited bleeding disorders.Source-grounded · automated review · Explore ↗
02Who is involvedBacked by BioGeneration Ventures (BGV), Angelini Ventures, Kurma Partners, severalFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedRougeTx raised $58M Series A, announced 2026-10-07From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersThe funding supports first human testing for RTX-001, an HHT treatment candidate.Source-grounded · automated review · Explore ↗
Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
RougeTx · Financing Record
Explore source-linked visual explanations for RougeTx. Unsupported claims are withheld while source review continues.
Record 13581 · Recorded date: 2026-10-07
Explore company records →